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Abstract: Surgical removal of wisdom teeth carries morbidity and significantly affects patients
quality of life. This study aims to investigate whether administration of low-level laser
therapy (LLLT) is effective in reducing post-operative morbidity in patients undergoing
surgical removal of mandibular third molars (MTM) compared to placebo.Material &
Methods: A systematic review and meta-analysis involving a comprehensive search
strategy implemented across five electronic databases. This was supplemented by
hand searching, contacting international experts and grey literature. Titles, abstracts
and full articles were scrutinised for studies meeting the inclusion criteria. All
randomised controlled trials (RCT) comparing treatment group of LLLT to a placebo
control group were eligible for inclusion. The outcomes variables were post-operative
pain, swelling and trismus. Risk of bias and methodological quality assessment was
carried out. We pooled data statistically and meta-analyses were carried out using a
random-effects model.Results;Seventeen RCTs were included in this systematic
review, all of which were considered to have a low risk of bias. Participants, aged 13-
70, and 35% female, totalled 1064. Meta-analyses found significant reductions in
standardised mean differences (SMD) in swelling at day 2 and day 7 postoperatively
(SMD -0.611, 95% CI -0.968, -0.234; SMD -0.532, 95% CI -0.795, -0.269). There were
non-significant reductions in SMD in pain and trismus at day 2 and day 7
postoperatively. Conclusion;LLLT significantly reduces swelling after extraction of MTM
compared to placebo. LLLT has not shown to reduce post-operative pain and trismus.
LLLT does not cause adverse effects. There is currently insufficient evidence available,
to promote the investment in LLLT versus the net clinical benefit. RCTs with larger
sample size and standardised study design and outcome measures are required, to
make definitive recommendations to clinicians on its use on patients.
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Dear Dr Hupp, 
Please can you consider this review article titled: ‘The use of laser therapy to reduce postoperative 
morbidity following third molar surgery. A systematic review and meta-analysis’ for publication in 
the Journal of Oral and Maxillofacial Surgery.  
This original article has not been published in another journal nor has it been currently submitted or 
accepted for publication elsewhere. This systematic review and meta-analysis has been registered 
on the website of the International Prospective Register of Systematic Reviews; PROSPERO. 
(PROSPERO 2018 CRD42018112018.  Available from: 
https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42018112018) 
In consideration of the Journal of Oral and Maxillofacial Surgery taking action in reviewing and editing 
our submission, the authors undersigned hereby transfer, assign, or otherwise convey all copyright 
ownership to the American Association of Oral and Maxillofacial Surgeons in the event that such work 
is published in the JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY. The undersigned authors 
understand that if the manuscript is accepted, the Editors reserve the right to determine whether it 
will be published in the print edition or solely in the Internet edition of the Journal. Articles accepted 
for publication are subject to editorial revision. 
The authors understand  that the editor reserves the right to edit manuscripts to fit the space available 
and to ensure conciseness, clarity, and stylistic consistency. 




REVISION COVER LETTER 
(Ms. Ref. No.: YJOMS-D-20-00976R1) 
 
Dear Dr Hupp, 
Thank you for your comments on the revised manuscript titled “Laser therapy reduces swelling, but 
not pain or trismus: a systematic review and meta-analysis.” 
 
I have made all changes as requested. I have itemised these below: 
 
(1) Please cite all references in numerical order in the text of the manuscript (Reference #15 does not 
appear to be cited and references 23, 45, and 46 appear to be out of order) 
 
The references have been adjusted. #15 error has been removed. Reference 23 has been moved to 
#31. References 46 and 46 have been changed to cite the 2009 publication before the 2010 
publication. 
 
I have uploaded this revision cover letter along with the revised manuscript via the relevant platform. 
 
Thank you for your patience with my hand-written references as I am experiencing difficulties with my 
referencing software. 
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“Laser therapy reduces swelling, but not pain or trismus: a systematic review and meta-analysis” 
Abstract 
Purpose 
Surgical removal of third molars carries morbidity and significantly affects patients’ quality-of-life. This 
study aims to investigate whether administration of low-level laser therapy (LLLT) is effective in 
reducing post-operative morbidity in patients undergoing surgical removal of mandibular third molars 
(MTM) compared to placebo. 
Material & Methods 
A systematic review and meta-analysis involving a comprehensive search strategy implemented across 
five electronic databases. This was supplemented by hand searching, contacting international experts 
and grey literature. Titles, abstracts and full articles were scrutinised for studies meeting the inclusion 
criteria. All randomised controlled trials (RCT) comparing treatment group of LLLT to a placebo control 
group were eligible for inclusion. The outcomes variables were post-operative pain, swelling and 
trismus. Risk of bias and methodological quality assessment was carried out. We pooled data 
statistically and meta-analyses were carried out using a random-effects model. 
Results 
Seventeen RCTs were included in this systematic review, all of which were considered to have a low 
risk of bias. Participants, aged 13-70, and 35% female, totalled 1064. Meta-analyses found  significant 
reductions in standardised mean differences (SMD) in swelling  at day 2 and day 7 postoperatively 
(SMD -0.611, 95% CI -0.968, -0.234; SMD -0.532, 95% CI -0.795, -0.269). There were non-significant 
reductions in SMD in pain and trismus at day 2 and day 7 postoperatively. 
Conclusion 
LLLT significantly reduces swelling after extraction of MTM compared to placebo. LLLT has not shown 
to reduce post-operative pain and trismus. LLLT does not cause adverse effects. There is currently 
insufficient evidence available, to promote the investment in LLLT versus the net clinical benefit. RCTs 
with larger sample size and standardised study design and outcome measures are required, to make  
definitive recommendations to clinicians on its use on patients. 
Keywords: laser, third molar, pain, swelling, trismus, morbidity 







































































Description of the condition 
An average of 25% of third molars are impacted and these teeth may require surgical removal1. The 
removal of third molars is not without complications. The general public is well aware of the common 
risks of third molar removal including pain, swelling and trismus. There are numerous other potential 
complications associated with removal of third molars; these include temporary or permanent 
damage to the inferior alveolar nerve, infection, bruising, damage to adjacent teeth, alveolar osteitis 
and in rare cases - fracture of the mandible2. 
Scale of the problem 
Patients experience significant disturbances in their quality-of-life (QoL) in the five days following third 
molar surgery3. One of the main reasons for patients being unhappy with their surgical treatment is 
the experience of pain. Also, patients do not respond well to treatment that, albeit temporary, causes 
them facial deformity in the form of facial swelling. Pain, swelling and trismus arise as a result of an 
inflammation cascade set off by the surgical procedure4. Traditional methods for minimising the 
sequelae of post-operative pain, swelling and trismus include the use of analgesia, corticosteroids and 
cryotherapy. However, these modes all have varying degrees of side effects. Alternative efficacious 
methods have been welcomed; such as low-level laser therapy (LLLT). The beneficial effects of lasers 
on human tissue were recognized in the 1960s and introduced in the medical field5. 
A high number of in-vitro studies found that low level lasers are capable of influencing pain levels by 
a sequence of events; downregulation of biochemical proteins such as prostaglandins (PGE2), 
interleukins (IL-1), tumor necrosis factor, inhibition of cyclo-oxygenase-2 and influencing redox 
reactions at a cellular level6. Also, by decreasing vessel size and permeability, the influx of pro-




































































laser is that it alters the central uptake and release of serotonin and acetylcholine and stimulates the 
production of endorphins while inhibiting bradykinin and C-fibers, thereby altering pain perception7. 
Other in-vitro studies have seen an increase in fibroblasts levels with LLLT and other studies have 
found lasers to have an angiogenic effect8. It is thought that the organelle, mitochondria, is the first 
to absorb the light energy from the laser. The charged mitochondria will increase its production of 
adenosine-triphosphate, which will in turn, increase cellular turnover including proliferation of 
fibroblasts, growth factors and tissue oxygenation9. In terms of clinical application, this suggests that 
areas affected by injury where an acidic medium prevails resulting in poor cellular proliferation can be 
treated by laser therapy5. 
The current evidence on LLLT 
Examination of the evidence base revealed a systematic review and meta-analysis performed in 2012  
and updated in 20177,10. Conclusions drawn stated that LLLT did not show net benefits but bore no 
adverse effects. Since publication of these reviews, new randomised controlled trials (RCTs) have been 
published. 
Study question 
A study question was formulated as such: Do individuals undergoing surgical removal of impacted 
mandibular third molars have less post-operative pain, swelling and trismus with administration of 
low-level laser therapy compared to placebo?  
Hypotheses 
The investigators hypothesised that LLLT is effective in reducing pain, swelling and trismus after third 
molar surgery. The null hypothesis is that administration of low-level laser therapy has no effect on 






































































The specific aims of this study were to systematically review and meta-analyse the evidence on 
whether administration of low-level laser therapy is effective in reducing post-operative pain, swelling 
and trismus in patients undergoing surgical removal of lower third molars compared to placebo.  
MATERIALS AND METHODS 
Study design 
To address the research purpose, the investigators designed and implemented a systematic review 
modelled after the Cochrane Collaboration recommendations for systematic reviews, in accordance 
with the ‘Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA)’ guidelines11.  
The study population was composed of all publications on the topic of LLLT and surgical MTM removal 
up to May 2020. To be included in the sample, publications had to satisfy the following criteria: RCTs 
comparing efficacy of LLLT compared to placebo after surgical removal of third molars, LLLT operating 
at a wavelength between 600-1000nm of any regimen and reporting outcomes of pain, swelling or 
trismus. No restrictions were placed on subject characteristics. No language barriers were placed, and 
non-English texts were translated.  
Publications were excluded from the analyses if they did not have a placebo arm or were non-human 
studies.  
Due to the retrospective nature of this study, it was granted an exemption from formal ethical 
approval in writing by the University of Central Lancashire Institutional Review Board. This study has 






































































Treatment group  
The treatment groups included subjects having received LLLT after surgical removal of MTMs. LLLT, 
known as biostimulation, causes a photochemical effect that  can upregulate metabolism resulting in 
wound healing and reduce inflammatory processes. All lasers defined as low-level with a wavelength 
of 600-1000nm were included. All laser types such as diode lasers, infrared lasers, helium-neon and 
gallium-aluminium-arsenic lasers were included. The power generated by these respective lasers was 
between 10-500mW. The duration of application were between 15 and 180 seconds with an energy 
output between 3-12J/cm2. Laser emission was either continuous or intermittent. The timing of laser 
therapy was either pre-operative, immediate post-operative or delayed post-operative, in either 
single or multiple applications. The laser was applied either intra or extraorally or both. The authors 
were not comparing efficacy of different laser types, wavelengths, power, energy output and duration; 
therefore, outcomes involving these variables were pooled by calculating their weighted average 
across the treatment arms. Subgroup analyses were performed for intraoral and extraoral laser 
application. 
Control group 
All subjects in control groups had placebo therapy. The placebo involved mimicking application of laser 
therapy with absence of photon energy transfer. 
Predictor variables 
The primary predictor variables were postoperative pain, swelling and trismus and were reported for 
day 2 and day 7 postoperatively. For studies that did not include outcomes on these days, data 
obtained from the closest time point was considered.  
Pain can be defined as an unpleasant sensory and emotional experience associated with actual or 




































































reported outcome measure is an instrument that aims at measuring pain intensity and ranges across 
a continuum of values between 0 and 10. Mean postoperative pain values were used for meta-
analyses. 
Swelling or oedema is the result of fluid accumulation in the soft tissues. Measurement of swelling is 
challenging as it can present in different tissue planes and can be localised or diffuse. As such, 
measurements of swelling are rarely standardized. Subgroup analyses were conducted for the most 
used methods of swelling assessment; distance between tragus and commissure; distance between 
gonion and canthus and Amin & Laskin method (measured as distance between commissure and lower 
part of auricular lobe & distance between canthus and angle of mandible)13. 
Trismus describes the state of reduced mouth opening and is usually secondary to pain, swelling and 
pathology. It is measured in millimetres as the distance from the maxillary incisal edge to the 
mandibular incisal edge. Studies not using this method of assessment were not included in the meta-
analyses. 
Other variables 
Intrinsic variables such as age, sex and pain sensitivity are well recognized modifiers of pain, swelling 
and trismus. Extrinsic variables in the form of co-interventions such as antibiotics, analgesics, steroids 








































































A comprehensive search strategy was used and several databases were searched for published studies 
from inception of these respective databases to May 2020: Medline, Embase, Dentistry and Oral 
Sciences Source, Cumulative Index of Nursing and Allied Health Literature (CINAHL), Academic Search 
Complete, Cochrane Library. Ongoing and unpublished trials were searched on: World Health 
Organization (WHO) International Clinical Trials Registry Platform (ICTRP). Internet-based databases 
were also searched: www.ClinicalTrials.gov, www.controlledtrials.com, www.scholar.google.co.uk. 
References from eligible published studies were scrutinised by hand searching: Journal of American 
Dental Association, International Journal of Oral and Maxillofacial Surgery, British Journal of Oral and 
Maxillofacial Surgery. Grey literature search was performed on ‘OpenGrey’. Experts in the field were 
contacted if further information was required. Search was performed from conception of electronic 
databases. No search restrictions were placed at this stage. Search criteria can be found in Appendix 
A. 
Data collection method 
The results obtained from each of the 5 respective electronic databases were transferred to the 
referencing software Refworks©. Duplicate results were then eliminated. The title and abstracts of 
the remaining studies were then screened for eligibility and any non-relevant articles were excluded. 
Potential salient trials were assessed in full text format and cross-referenced against inclusion and 
exclusion criteria. Trials not meeting the inclusion criteria were eliminated. 
This process was performed in duplicate by two independent reviewers. Disagreements were resolved 
by consensus and when no consensus could be reached, a third investigator acted as an arbitrator. 
The final studies were evaluated by two investigators independently and in duplicate. Distillation of 
information was expediated using custom designed data extractions tables. The risk of bias in the 




































































two reviewers independently to reach a mutual consensus. Risk was classified as low, high or unclear. 
If data was missing, the authors were contacted to obtain information. 
Data analyses 
We pooled data statistically and conducted meta-analyses on available outcomes using a random-
effects model. All analyses were undertaken, and forest plots created using Comprehensive Meta-
Analysis software (version 3). Results were expressed as standardised mean differences (SMD) with 
95% confidence intervals (CI) for dichotomous outcomes. We performed statistical tests for 
heterogeneity based on I2 statistic. Relevant heterogeneity will be tested for using the I² statistic and 
significant heterogeneity assumed if I² is greater than 40% (i.e. more than 40% of the variability in 
outcome between trials could not be explained by sampling variation). We assessed for evidence of 
publication bias graphically using Funnel plots and statistically using Egger’s test14.  
In the analysis of swelling, models were selected based on the methods of assessing swelling: method 
1 – distance between tragus and commissure; method 2- Amin & Laskin method; method 3 – distance 
between gonion and canthus.  
RESULTS 
Description of studies 
Four hundred and sixty-two results were obtained from the five databases searched. Hand searching 
produced 5 additional papers making a total of 467 papers. Eighteen studies were excluded at the full 
text screening stage with justification7,10,15-30. Seventeen studies met the inclusion criteria1,31-46. The 
flow of information is illustrated in a PRIMSA diagram, see Figure 1. 
All 17 studies were randomised controlled trials. However, the study designs varied. Nine studies had 
a split-mouth design33-37,40-42,46. The rest of the studies had parallel designs1,31,32,38,39,43-45. All 17 studies 




































































A total of 1064 study subjects participated across the 17 studies. Two studies did not record participant 
gender and age31,43. The study subjects were aged between 16- 70 years and there were 370 recorded 
female subjects. All studies took place in a hospital setting. The general characteristics of included 
studies is presented in Table 1. 
 
All 1064 study subjects in the studies had surgical removal of their lower third molars followed by 
either laser therapy or placebo. However, the LLLT regimens varied in the type of LLLT used, the 
approach, power, site and duration of application. Table 2 presents the LLLT regimen employed within 
each study. Several co-interventions were also employed within the studies. Subjects had prophylactic 
antibiotic in nine studies1,32,34-37,42,44-46. Seven studies provided oral acetaminophen to be taken post-
operatively27,32,35,40,41,44,45. Six studies prescribed non-steroidal anti-inflammatory (NSAID) post-
operative medication 1,34,36,37,42,46. All 17 studies had used placebo as a comparator1,31-46. 
 
Risk of bias of included studies 
Using the ‘Cochrane Risk of Bias Assessment Toolkit’, seven studies had adequate randomization 
processes33-36,38,39,46. Ten studies stated that their study subjects were randomized but did not specify 
their method of randomization1,31,32,37,40-45. One study discussed allocation concealment33. Three 
studies mentioned that subjects were randomized only after the surgery was performed1,38,40. By 
randomizing after the surgery, both the surgeon and patient would be unaware of future treatment 
allocation. Surgeons were blinded in five studies33,34,37,38,42. Three studies used different surgeons to 
perform the surgery and administer the laser, but it was unclear as to whether the surgeons were 
blinded31,32,35. All study subjects in the 17 studies were blinded to the intervention they received1,31-46. 
Three studies had made available their study protocol31,33,38. In 16 studies, the prespecified outcomes 




































































size calculation33. Treatment and follow-up protocols were the same for both treatment and control 
groups across the studies. Seven studies declared no interests1,31,32,34-36 and three studies declared 
funding43,44,46. After consideration of each domain, calculation of an overall risk of bias for each study 
found that all 17 studies had a lower overall risk of bias1,31-46. Figure 2 illustrates a traffic light system 
to categorise the risk of bias for each respective domain for each study. 
Efficacy of LLLT 
Pain 
Fifteen studies, with a total of 66 subjects, measured pain1,31,32-43,46. Ten studies found that LLLT 
reduces pain in subjects post-operatively1,32,35-38,40,41,46. Five of these studies reported that the pain 
reduction was statistically significant32,34,37,38. Three studies found no clinical nor statistical difference 
in pain levels between the treatment and control group31,33,43. In one study, LLLT showed higher pain 
scores compared to placebo in the four hours after surgery39. The included trials had a degree of 
variation in the times at which measurements were performed; the statistical analysis and the study 
designs. Saber et al., in addition to pain intensity, also measured pain duration. Laser group 
participants had shorted duration of pain compared to control groups in that study38. 
Five out of 15 studies that reported pain, demonstrated homogeneity and were included in meta-
analyses.  The results showed not significant reductions in standardised mean differences (SMD) for 
pain on day 2 and day 7  in the intervention group compared to the control group(SMD -0.502, 95% CI 
-1.038, 0.034; SMD -0.244, 95% CI -0.542, 0.053, respectively). See Figures 3 & 4. The funnel plot 
suggests there is potential publication bias based on asymmetry; however, the Eggers regression 
intercept suggests publication bias14. It is important to note however that this must be interpreted 
with caution as it has been suggested the use of this test with less than 10 studies reduces its power47. 







































































Eleven studies, with a total of 380 subjects, looked at swelling as an outcome measure1,32,33,36,37,40,42-46.    
The measurement of swelling differed across the studies. Most swelling measurements were taken as 
the distance between two facial points. Facial landmarks used were: tragus, commissure of mouth, 
gonion, canthus and auricular lobe. Two studies used the Amin and Laskin method44,45. Two studies 
used observed values42,43. One study used a 3-dimensional photogrammetric system to measure 
volumetric postoperative swelling32. Seven of these studies found clinically important reduction in 
facial swelling among the laser groups compared to the placebo groups1,32,36,37,42,43,44. Only 2 studies 
showed statistically significant reduction in swelling between laser and control group44,46.  
Five out of 11 studies demonstrated homogeneity and were included in the meta-analyses.  The 
overall analysis of these five studies demonstrated significant reductions in swelling with either 
intraoral or extraoral application of LLLT on day two in the models with swelling assessment method 
(SMD -0.557, 95%CI -0.925, -0.189 and SMD -0.611, 95%CI -0.988, -0.234, respectively). See Figures 6 
& 7. 
The overall analysis of the five studies also found significant reductions in swelling with both intra-oral 
and extra-oral application of LLLT in Aras et al. 2010 and with swelling coefficient as the method of 
swelling assessment in Eshghpour et al. 2016 on day 7 (SMD -0.513, 95%CI -0776, -0.250 and SMD -
0.532, 95%CI -0.795, -0.269, respectively). See figures 8 and 9. 
Analysis of three studies that used tragus to commissure as the method of swelling assessment found 
a not significant reduction in swelling on day two (SMD -0.448, 95%CI -0.968, 0.071) and a statistically 
significant reduction on day seven (SMD -0.443, 95%CI -0.786, -0.101) in the LLLT group compared to 
the control group. See Figures 10 & 11. 
 
Analysis of two studies that used Amin & Laskin method as their method of swelling assessment found 




































































on day two (SMD -0.760, 95%CI -1.326, -0.195  and SMD -0.931, 95%CI -1.448, -0.415, respectively) 
and day seven (SMD -0.667, 95%CI -1.172, -0.163 and SMD -0.740, 95%CI -1.247, 0.233, respectively). 
See Figures 12, 13, 14 & 15. 
 
Analysis of two studies that used distance between gonion and canthus as their method of swelling 
assessment found a significant reduction with LLLT on day two (SMD -0.603, 95%CI -1.112, -0.094) but 
not on day seven (SMD -0.441, 95%CI  -1.740, 0.858, respectively). See Figures 16 & 17.  
 
Trismus 
Eleven studies, with a total number of 398 study subjects, measured trismus1,32-34,36,39,41,43-46. Two of 
them found statistically significant reduction in trismus with laser group compared to placebo39,44. The 
most popular method of measurement was distance from upper central incisors to lower central 
incisors. One study measured percentage trismus39 and one study used observed values43.  
Six out 11 studies, demonstrated homogeneity and were included in the meta-analyses. The results 
showed no difference between LLLT and control groups, regardless of site of laser in Aras et al 2009, 
2010  and day of assessment in Farhadi et al. 2017  were included in the models. Figures 18 & 19 
present respective results for day two (SDM 0.002, 95%CI -1.159, 1.163 and SDM 0.075, 95%CI -1.187, 









































































The purpose of this study was to investigate the benefits of LLLT in post-operative healing after surgical 
exodontia. The authors hypothesized that LLLT was effective in reducing post-operative sequelae after 
oral surgery. The null hypothesis was that administration of LLLT had no effect on post-operative 
healing. The specific aims of this study were to systematically review and meta-analyse the evidence 
on whether administration of low-level laser therapy was effective in reducing post-operative pain, 
swelling and trismus in patients undergoing surgical removal of lower third molars compared to 
placebo. 
Seventeen RCTs were included in the review1,31-46. Data was statistically pooled to achieve meta-
analyses for each overall outcome.  
The results of this study show statistically significant reduction in post-operative swelling with the use 
of LLLT compared to placebo after dental surgery. LLLT does not significantly reduce pain or trismus 
after surgery as compared to placebo.  
While statistical significance indicates the reliability of the study results, clinical significance reflects 
its impact on clinical practice. Many studies included in this review generalised statements on clinically 
important differences and statistical significance as related to the outcome variables. However, no 
studies, described clear parameters on what they considered to be clinically significant. 
Ten out of seventeen studies reported clinically important positive differences in pain levels with the 
laser group compared to the placebo group1,32,35-38,40,42,46. However, only five of these respective 
studies showed statistically significant improvement32,34,35,37,38.  
Seven studies demonstrated clinical reduction in swelling in the LLLT over the control group1,32,36,42-44. 
However, only two of these demonstrated this reduction in swelling with LLLT over placebo to be 
statistically significant37,44. Investigators across the studies used different facial landmarks or observed 
values to measure swelling. This heterogeneity may account for the lack of consistency in the 




































































From the eleven studies that reported on trismus as an outcome measure, two of them demonstrated 
statistically significant reduction in trismus in LLLT group compared to control39,44. Four of them found 
LLLT to have no net benefit in reducing trismus following third molar surgery1,32,33,36. 
With regards to extrinsic variables in the form of co-interventions, post-operative medication was 
given in most of the studies1,32-37,40-46. The medications included antibiotics, analgesia and 
mouthwashes. Co-interventions along with LLLT can certainly confound the findings. Due to the fact 
that co-interventions were the same in treatment and control groups, any size of treatment effect 
would be attributed to the laser alone. The lack of standardization in both intrinsic and extrinsic 
variables across the studies did not allow pooling of data and effect measurement. 
All studies lasted at least seven days1,31-46. A seven day follow up period is appropriate as the sequelae 
of IMTM surgery is short lived36. Pain, swelling and trismus are at their highest in the first 2 to 3 days 
after surgery and mostly subsides by the seventh day. 
Three studies received funding43,45,46 and 7 studies declared no conflict of interests31,32,34-36,43,44. Three 
studies specifically stated that LLLT bore no negative outcomes33,35,36. Thus, it appears that application 
of LLLT is safe as there is no evidence to suggest otherwise. 
This systematic review and meta-analysis updated the evidence presented by Brignardello et al. and 
Dawdy et al on the use of low-level laser therapy in reducing the post-operative complications of pain, 
swelling, trismus following surgical removal of impacted third mandibular molars7,10. 
Brignardello et al. reported that LLLT was not effective in reducing pain and swelling, but effective in 
reducing trismus after removal of IMTMs compare to placebo7. Dawdy reported negligible benefits 
from LLLT10. This is not mirrored by the findings of this review which concluded a significant reduction 
in swelling but pain or trismus following surgery. 
The recommendations stated by Brignardello et al. on the need for more well-reported RCTs with 




































































followed7. The new studies had low overall risk of bias, they administered laser therapy at the same 
time, most of them used the VAS for pain measurement and trismus measurements were 
standardised. 
This review had several strengths. First, the searches were conducted with high methodological rigour 
involving comprehensive searches and including all available sources from five electronic international 
databases. Characteristics of all search terms including MeSH and free keywords for this topic were 
carefully identified and scrutinised. In addition, we contacted an international panel of experts. A 
comprehensive search strategy would ensure that no relevant studies would be inadvertently 
excluded.  
Second, this review included 17 studies, totalling 1064 study subjects compared to Brignardello et al. 
who reported on 10 studies involving 740 subjects7. Our significant sample size increases the study 
power.  
Third, all included studies were high quality randomized controlled trials with low risk of bias. On the 
pyramid of hierarchy of evidence, this is Level 1b evidence, which is the most robust type of empirical 
evidence when assessing the outcome of an intervention.  
Fourth, all the subjects across the studies were treated in a hospital setting. This is in line with the fact 
that surgical removal of MTMs require specialist intervention. Presumably, the level of competence 
of the surgeons would be similar across the trials; which further standardizes the surgery. This ensures 
that any difference in outcome assessment is down to the intervention (i.e LLLT) alone. 
All recruits across the studies required surgical removal of MTMs. This strict inclusion criteria ensured 
that the outcome assessments were not confounded by differences in baseline characteristics. The 17 
included studies were performed in several countries across the world. The results of this study are 
therefore generalizable internationally as the study populations came from both economically 




































































The main limitations of this systematic review stem from the heterogeneity; both clinical and 
methodological of included populations, diversity of measuring outcomes and their definitions. The 
results of both split mouth and parallel trials were pooled together. The significance of the 
heterogeneity in study design is not known; however, despite differences in study approach, the 
designs were of high quality and low risk of bias, minimizing risk of spurious findings.  
 The non-significant data on pain and trismus does not mean that there is no efficacy of the 
intervention compared with controls. Several factors may play a role, including small sample size 
issues in our meta-analyses. Due to the heterogeneity of included studies, the conducted meta-
analyses need to be interpreted with caution. 
Despite the postulated benefits of LLLT after surgery, there are still barriers to its use and 
implementation in oral and maxillofacial clinics. Implementation of laser treatment requires capital 
investment in the form of equipment, training and clinical time. Furthermore, implementation of any 
novel therapy has a significant learning curve. None of the studies have discussed the cost implications 
and effectiveness of laser provision compared to pharmaceutical management. On the surface, 
pharmaceutical management after removal of third molars appears to be a cost-effective option that 
does not require additional investment. Estimates on the cost of a helium-neon laser is from $14,000. 
Additional training costs make this a high initial investment therapy. So far, there is insufficient 
evidence to recommend this investment as a standard of practice for oral surgery.  
Furthermore, no studies have completed an oral health related quality of life (OHRQoL) assessment 
on the use of LLLT following surgical removal of MTMs. The authors are therefore unable to comment 
on the impact of LLLT on quality of life (QoL) following oral surgical procedures. As such, this would be 
an area of interest for future research. 
In conclusion, adults undergoing surgical removal of impacted mandibular third molars have 
significantly less postoperative swelling with administration of low-level laser therapy compared to 




































































have less postoperative pain and trismus with administration of low-level laser therapy compared to 
placebo. 
Few studies have investigated the use of low-level laser therapy after surgical removal of impacted 
mandibular third molars; therefore, this study makes a significant contribution to the evidence base. 
There is, however, not yet enough evidence to promote the investment involved with the routine use 
of laser therapy after third molar surgery. 
Future, high quality RCTs with standardization of study designs, outcome measures and LLLT regimen, 
together with an investigation into its cost-effectiveness would serve to better advise patients, doctors 
and policy makers about the use of low-level laser therapy in patients undergoing removal of impacted 
mandibular third molars. 
Disclosure. The authors did not report any interests. This research did not receive any specific grant 
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Table 1. Characteristics of included studies. 





Carillo et al., 
1990 
Parallel Mean 27 67F 33M 34 34 
Clokie et al., 
1991 
Split-mouth Range 16-25 10F 5M 15 15 
Fernando et 
al., 1993 
Split-mouth Range 18-50 Not recorded 64 64 
Braams et al., 
1993 
Split-mouth Range 17-35 24F 19M 43 43 
Fikackova et 
al., 2003 
Parallel Not recorded Not recorded 1 1 
Aras et al., 
2009 
Parallel Range 18-27 21F 11M 16 16 
Aras et al., 
2010 
Parallel Range 18-27 34F 14M 32 16 
Lopez-
Ramirez et al., 
2017 
Split mouth Range 18-37 11F 9M 20 20 
Saber et al., 
2012 
Parallel Range 18-70 50F 50M 50 50 
Sierra et al., 
2015 
Parallel Range 13-60 Not recorded 40 20 
Eroglu et al., 
2016 
Split-mouth Range 18-40 15F 20M 35 35 
Eshghpour et 
al., 2016 
Split-mouth Range 18-35 24F 20M 44 44 
Kahraman et 
al., 2017 
Split-mouth Range 16-35 36F 24M 60 60 
Farhadi et al., 
2017 
Parallel Range 18-35 24F 24M 24 24 
Hamid et al., 
2017 
Split-mouth Range 19-29 16F 14M 30 30 
Sampaio et 
al., 2018 
Split-mouth Range 18-28 13F 29M 42 42 
Asutay et al., 
2018 









































































Table 2. Low level laser therapy regimen employed across the included studies 
 
Study Type Wavelength Power Energy Site Duration Mode Timing Comparison 
Carillo et al., 
1990 






Clokie et al., 
1991 
He-Ne 632.8nm 10mW 
Not 
recorded 
Intraoral 180s Continuous Postoperatively Placebo 
Fernando et 
al., 1993 
Ga-Al-As 830nm 30mW 4J/cm² Intraoral 132s Intermittent Postoperatively Placebo 
Braams et 
al., 1994 
Ga-Al-As 829mn 30mW NR Intraoral 66s 
Not 
recorded 
Not recorded Placebo 
Fikackova et 
al., 2003 
Ga-Al-As 830nm 200mW/cm² 12J Intraoral 108s Intermittent 




Aras et al., 
2009 







Aras et al., 
2009 
Ga-Al-As 808nm 100mW 12J 
Intraoral 
Extraoral 




Ga-Al-As 810nm 500mW 4j/cm² Intraoral 32s Continuous Postoperatively Placebo 
Saber et al., 
2012 
Diode laser 810nm 100mW 5J/cm² Intraoral 
Not 
recorded 
Continuous Postoperatively Placebo 













Continuous Not recorded Placebo 
Eroglu et al., 
2016 
Diode laser 940nm 275mW 50J Extraoral 
Time to 
reach 50J 
Continuous Postoperatively Placebo 
Eshghpour 










Continuous Not recorded Placebo 
Kahraman 
et al., 2017 


























































































Diode laser 550nm 100mW 5J/cm² Intraoral 25s Continuous Postoperatively Placebo 
Hamid et 
al., 2017 




















































































1 MH molar third 
2 MH tooth impacted 
3 MH tooth extraction 
4 Exodontia 
5 lower third molar 
6 third molar 
7 third molar surgery 
8 t??th extract* 
9 dental extraction 
10 wisdom t??th 
11 impact* t??th 
12 mandibular t??th 
13 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 
  
14 MH low-level light therapy 
15 MH laser therapy 
16 MH lasers 
17 laser* 
18 laser irradiation 
19 LLLT 
20 laser therapy 
21 low level light therapy 
22 low level laser therapy 
23 #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 
  
24 MH pain 
25 MH pain measurement 
26 MH pain postoperative 
27 pain 
28 discomfort 
29 postoperative pain 
30 #24 OR #25 OR #26 OR #27 OR #28 OR #29 
  




35 #31 OR #32 OR #33 OR #34 
  
36 MH trismus 
37 trismus 
38 mouth opening 
39 lock* jaw 
40 #36 OR #37 OR #38 OR #39 
  
41 treatment outcomes 
42 wound healing 





































































44 #30 OR #35 OR #40 OR #43 
  



































































































Figure 1. PRISMA diagram illustrating flow of information from search strategy to final included 
studies. 
 
Figure 2: Risk of bias analysis of the included studies 
Figure 3. Forest plot showing standardised mean differences and 95% CI for changes in pain 
reduction on day 2 after LLLT vs controls following third molar surgery (random-effects model). 
 
Figure 4. Forest plot showing standardised mean differences and 95% CI for changes in pain 
reduction on day 7 after LLLT vs controls following third molar surgery (random-effects model). 
 
 Figure 5. Funnel plot showing SMD of pain reduction following LLLT intervention vs controls. 
 
Figure 6 (overall). Forest plot showing standardized mean differences and 95% CI for swelling on day 
2 after LLLT vs control following third molar surgery (random-effects model) [Aras Intra-oral laser] 
 
Figure 7 (overall). Forest plot showing standardized mean differences and 95% CI for swelling on day 
2 after LLLT vs control following third molar surgery (random-effects model) [Aras extra-oral laser] 
 
Figure 8 (overall). Forest plot showing standardized mean differences and 95% CI for Swelling on day 
7 after LLLT vs control following third molar surgery (random-effects model) [Eshghpour 2016 a = 
Distance between tragus and commissure (swelling coefficient) - Aras 2010 Intra-oral laser] 
 
Figure 9 (overall). Forest plot showing standardized mean differences and 95% CI for Swelling on day 
7 after LLLT vs placebo following third molar surgery (random-effects model) [Eshghpour 2016 a = 
Distance between tragus and commissure (swelling coefficient) - Aras 2010 Extra-oral laser] 
 
Figure 10. Forest plot showing standardized mean differences and 95% CI for Swelling (tragus to 
commissure) measurement on day 2 after LLLT vs placebo following third molar surgery (random-
effects model) 
 
Figure 11. Forest plot showing standardized mean differences and 95% CI for Swelling (tragus to 
commissure) on day 7 after LLLT vs placebo following third molar surgery (random-effects model). 
 
Figure 12. Forest plot showing standardized mean differences and 95% CI for swelling (Amin & Laskin 
method) on day 2 after LLLT (intra-oral laser) vs control following third molar surgery (random-
effects model) 
 
Figure 13. Forest plot showing standardized mean differences and 95% CI for swelling (Amin & Laskin 






































































Figure 14. Forest plot showing standardized mean differences and 95% CI for swelling (Amin & Laskin 
method) on day 7 after LLLT (intra-oral laser) vs control following third molar surgery (random-
effects model) 
Figure 15. Forest plot showing standardized mean differences and 95% CI for swelling (Amin & Laskin 
method) on day 7 after LLLT (extra-oral laser) vs control following third molar surgery (random-
effects model) 
 
Figure 16. Forest plot showing standardized mean differences and 95% CI for swelling (gonion & 
canthus) on day 2 after LLLT vs control following third molar surgery (random-effects model) 
 
Figure 17. Forest plot showing standardized mean differences and 95% CI for swelling (gonion & 
canthus) on day 7 after LLLT vs control following third molar surgery (random-effects model) 
 
Figure 18. Forest plot showing standardized mean differences and 95% CI for trismus on day 2 after 
LLLT vs control following third molar surgery (random-effects model) [For Aras 2010 extra-oral laser 
data used - Farhadi 2017 day 1] 
 
Figure 19. Forest plot showing standardized mean differences and 95% CI for trismus on day 2 after 
LLLT vs control following third molar surgery (random-effects model) – [ For Aras 2010 intra-oral 
laser data used - Farhadi 2017 day 1] 
 
Figure 20. Forest plot showing standardized mean differences and 95% CI for trismus on day 7 after 
LLLT vs control following third molar surgery (random-effects model) [ For Aras 2010 intra-oral laser 
data used] 
 
Figure 21. Forest plot showing standardized mean differences and 95% CI for trismus on day 7 after 
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producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.  The financial relationships are 
identified as follows (if needed, attach an additional list): 
 RELEVANT FINANCIAL RELATIONSHIP(S) RELATED TO YOUR CONTENT (CHECK ALL THAT APPLY) 
Commercial Interest(s) 
(any entity producing, marketing, re-selling, or 
distributing health care goods or services 
consumed by, or used on, patients.) 
Research Grant 
(including funding to an 







Consultant Other (Identify) 
	 	 	 	 	 	
	 	 	 	 	 	
 
 
___ 3rd Co-Author (if applicable) 
 
Name:  _____________________________________________________ ______________________________________________ 
 
DISCLOSURE OF FINANCIAL RELATIONSHIPS WITHIN 12 MONTHS OF DATE OF THIS FORM 
 
____ NO—Neither I, nor any member of my immediate family, has a financial relationship or interest (currently or within the past 12 months) with any 
entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. 
 
OR 
____ YES--I have or ___an immediate family member has a financial relationship or interest (currently or within the past 12 months) with any entity 
producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.  The financial relationships are 
identified as follows (if needed, attach an additional list): 
 RELEVANT FINANCIAL RELATIONSHIP(S) RELATED TO YOUR CONTENT (CHECK ALL THAT APPLY) 
Commercial Interest(s) 
(any entity producing, marketing, re-selling, or 
distributing health care goods or services 
consumed by, or used on, patients.) 
Research Grant 
(including funding to an 







Consultant Other (Identify) 
	 	 	 	 	 	









___ 4th Co-Author (if applicable) 
 
Name:  _____________________________________________________ ______________________________________________ 
 
DISCLOSURE OF FINANCIAL RELATIONSHIPS WITHIN 12 MONTHS OF DATE OF THIS FORM 
 
____ NO—Neither I, nor any member of my immediate family, has a financial relationship or interest (currently or within the past 12 months) with any 
entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. 
 
OR 
____ YES--I have or ___an immediate family member has a financial relationship or interest (currently or within the past 12 months) with any entity 
producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.  The financial relationships are 
identified as follows (if needed, attach an additional list): 
 RELEVANT FINANCIAL RELATIONSHIP(S) RELATED TO YOUR CONTENT (CHECK ALL THAT APPLY) 
Commercial Interest(s) 
(any entity producing, marketing, re-selling, or 
distributing health care goods or services 
consumed by, or used on, patients.) 
Research Grant 
(including funding to an 







Consultant Other (Identify) 
	 	 	 	 	 	
	 	 	 	 	 	
 
 
___ 5th  Co-Author (if applicable) 
 
Name:  _____________________________________________________ ______________________________________________ 
 
DISCLOSURE OF FINANCIAL RELATIONSHIPS WITHIN 12 MONTHS OF DATE OF THIS FORM 
 
____ NO—Neither I, nor any member of my immediate family, has a financial relationship or interest (currently or within the past 12 months) with any 
entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. 
 
OR 
____ YES--I have or ___an immediate family member has a financial relationship or interest (currently or within the past 12 months) with any entity 
producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.  The financial relationships are 
identified as follows (if needed, attach an additional list): 
 RELEVANT FINANCIAL RELATIONSHIP(S) RELATED TO YOUR CONTENT (CHECK ALL THAT APPLY) 
Commercial Interest(s) 
(any entity producing, marketing, re-selling, or 
distributing health care goods or services 
consumed by, or used on, patients.) 
Research Grant 
(including funding to an 







Consultant Other (Identify) 
	 	 	 	 	 	
	 	 	 	 	 	
 
 
___ 6th Co-Author (if applicable) 
 
Name:  _____________________________________________________ ______________________________________________ 
 
DISCLOSURE OF FINANCIAL RELATIONSHIPS WITHIN 12 MONTHS OF DATE OF THIS FORM 
 
____ NO—Neither I, nor any member of my immediate family, has a financial relationship or interest (currently or within the past 12 months) with any 
entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. 
 
OR 
____ YES--I have or ___an immediate family member has a financial relationship or interest (currently or within the past 12 months) with any entity 
producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.  The financial relationships are 
identified as follows (if needed, attach an additional list): 
 RELEVANT FINANCIAL RELATIONSHIP(S) RELATED TO YOUR CONTENT (CHECK ALL THAT APPLY) 
Commercial Interest(s) 
(any entity producing, marketing, re-selling, or 
distributing health care goods or services 
consumed by, or used on, patients.) 
Research Grant 
(including funding to an 







Consultant Other (Identify) 
	 	 	 	 	 	
	 	 	 	 	 	
 
